They could do a combo cash and convert. Also they could use their stock as currency now that it's risen. That's the value of being a public company.
They're getting ready, I think, for a big acquisition in the $200 - 250MM range, May float a convert which arbs will inevitably short, but the deal will be well received by the Street. For DEPO, cash was king in 2013. In 2014 they may use a little leverage to boost profitiability and surprise everyone. Just a guess on my part. Biotech analysts love positive surprises and punish the bad ones. DEPO's a darling this year.
Now you know why they dont need to raise money. Had they enlisted the help of an investment banker the share price would probably be higher in the short run due to sponsorship, but management is dilution conscience. They still may need to do a secondary for a large acquisition which would be a big positive.
Lobbying effort in place for increased cultivation of opium poppies in Tasmania. Otherwise, big pharma may have to buy from the Taliban.
Book value is accurate, but expense management is totally lacking. However, it looks like D-wave is being primed for an IPO. One doesn't have to like this Company's management to make money on the stock. Looks like we are at the start of an uptrend.
Sometimes, DEPO falls intra-day when MNK is weak. Some investors are trading the two stocks in tandem. Volume is higher now in MNK. It will be interesting if there's no news by Monday, since DEPO will be speaking at the Roth Conference.
I don't think the FDA would punish MNK and DEPO due to Depo's lawsuit. DEPO was very respectful of the Agency in their public statements; it's just business, as usual. Besides, the FFA is a hige, dysfunctional beureaucracy where one department barely talks to the other and reviewers go through a revolving door, eventually working for industry.
We're also witnessing a flurry of press releases, all of which is important stuff for the companies they invested in. Traders and institutions have been taking tax losses on this stock for over a year. This stock has flatlined longer than I can remember. But now it appears to be bottoming out. They're really trying to get the word out on their incubee's activities. Today's p.r. about Metabolin's work with Craig Ventner is the real thing. Hopefully, they can monetize their investments enough to suprass the expense budget. Eventually, the selling pressure will end and we can see a bounce. When it happens is difficult to predict. All I know is that alot of old stock has coe in over the past couple of years and eventually that selling pressure will dry up. There's no need for a company like this to be selling at a 25% discount to NAV.
I think the Company is being quite mum. We don't know the earnings date, we're almost a week late on the Xartmies PDUFA date, Obama and Congress are talking about repatriating assets which could make a sudden move to Ireland (through a takeover a possibility). All of this creates some nervousness as well as opporunity.
I spelled it wrong . It's Oxecta and Acura (ACUR) makes the drug delivery system for Pfizer.
I would expect a similar approval for Xartemis from MNK-DEPO.
Sounds gross, but it's actually important in medicine. The Chinese knew about this a long time ago with legendary Bird's Nest Soup(high in mucin). Mucin Factor 4 is being studied for ulcerative colitis and g.i. docs have long known about mucoprotective agents. The key aspect will be the delivery system to the colon.
My mistake: In today's SEC Filing, INSY just reported that they had $45MM on their balance sheet at the end of the year, not $32MM, as reported by Yahoo. This morning they released their annual report, but not their proxy statement, so we don't know where the ownership lies. We do know that with ast year's IPO, the preexisting debt to the Kapoor trust was extinguished and converted to 7 million+ shares at a price of $8. One would assume that the Kapoor, Executive Chairman of INSY, is the largest shareholder.
on several fronts:
Top 10 in Extended Hours Trading Volume
Top 10 in Percentage Volume Increase During Total Trading Day
Top 10 in Largest Block Trades
Top 10 March Hockey Stick Stocks (Based on Exponential Price:Volume Action)
This may bring in a few momentum players.
Market Cap:800 MM vs 1.8MM
Fentanyl Sales: ? Too Early to Tell, Maybe Only $5MM in Trailing Q vs. $45 MM
Cash: $250+MM vs. ~$35MM
Approved Products: 4 vs. 2
Patent Estate: Validated to 2020 vs. I.P. Competitive Pressures
Partnerships: 2 Big Pharma with two high single digit royalties vs. None That We Know Of
Cannabinoid Pipeline: None vs. Strong Platform in Competitive Landscape
Legacy: Old Struggling Stock form the early 90s with Recent Metoric Rise vs. Remake IPO with Stratospheric Rise
The first two were a cross. The buyer tried to bring down the share price briefly yesterday as they did on Friday to scare the nervous nellies. When that didn't work, they brought it back to 14. The last print was open ended and may bring the stock higher. INSY, another maker of Fentanyl, sublingual similar to Actiq, jumped yesterday aftyer announcing a 3:2 stock split. Hedge fund quants use subsector algorhythms (fentany; based pain stocks) i their technical analysis. Once their value driven analysts see how cheap DEPO is compared to INSY they may suck out the overhead for a gapper.
I would expect it to be Schedule 2. Perhaps the second drug, which is less potent could go Schedule 3. I'm not very knowledgable about these designations.,but in either event there will be a computer provider cross-reference to preclude multiple prescriptions
If they receive a CRL, DEPO and MNK will drop. If they receive approval, regardless of the label, both stocks will soar. If MNK is buying DEPO, they may release both news events at the same time.